No Data
No Data
Renaissance - significant increase, upward revision of performance for the fiscal year ending March 25th.
Sharply extended. After the close of trading on the 3rd, the upward revision of performance was announced and well received. The business revenue for the 25th fiscal year was revised upward from 90 million yen to 150 million yen, and the ordinary loss was revised upward from a deficit of 275 million yen to a deficit of 257 million yen, and the deficit is expected to shrink. The reason for the revision is that the US company Eirion Therapeutics, which has entered into a license agreement granting exclusive implementation rights for RS5441 (transdermal and oral drugs) for the treatment of skin diseases, is conducting a phase I clinical trial.
Renascience, GMO ◆ Today's hot stocks by FISCO ◆
Lena Science <4889> announced a revision of its financial estimates for the fiscal year ending March 2025. The revenue has been revised upwards from 90 million yen to 105 million yen, while the operating loss has been revised upwards from a loss of 275 million yen to a loss of 257 million yen, due to the start of Phase 1 clinical trials at Eirion Therapeutics, Inc. in the United States, which is expected to receive a milestone payment of $100,000 from Eirion. GMO <9449> stock prices reached a high on May 16th.
Strong, supported by low long-term US interest rates.
[Emerging Market Individual Stock Strategies] Today's emerging market is expected to develop strongly. In the U.S. stock market on the 3rd, the Dow Jones fell slightly by 23.85 dollars (-0.06%) to 39,308.00 dollars, marking a small fall for the third straight day. The market was supported by a weak labor-related indicator announced in the morning and a drop in long-term interest rates, amid a lack of momentum in the shortened trading session ahead of Independence Day. The Nasdaq index, pushed up by gains in Tesla and Nvidia, hit a record high and closed higher. Buy emerging markets today.
Delta-P, Tim's, and others
<3803> Established an imaging subsidiary <4598> Started clinical phase III comparative trial registration of Delta-PDFP-14323 <4889> Upside revision by Lina Science; expected operating loss of -257 million yen this fiscal year ← -275 million yen <usa> Launched phase I clinical trial at Eirion Therapeutics, Inc. <4891> Signed exclusive implementation license agreement with Hokkaido universities for a new treatment candidate for spinal cord injuries <universities> <7078> <No translation found>
ABC Mart's operating profit in 1Q increased by 9.0% to 18.4 billion yen.
ABC Mart <2670> announced its first quarter performance for the February 2025 fiscal year, with revenue totaling 96.215 billion yen, an increase of 8.6% compared to the same period last year, and operating profit of 18.408 billion yen, a 9% increase from the same period last year. Despite the increasingly strict customer selection due to rising commodity prices, high value-added items such as products with strong practical demand and trending products are experiencing increasing demand. In Japan, sales in the city centers, grand stages, and large commercial facilities have been robust. [Positive evaluation] <4889> Rena.
Renascience: Announcements of individual stock financial estimates revision for the full year ending March 2025.
No Data